Click here to read the complete article.
Abstract Title:Astragaloside IV Improves the Barrier Damage in Diabetic Glomerular Endothelial Cells Stimulated by High葡萄糖和高胰岛素。
抽象来源:
基于EVID的补体替代药物。 2022; 2022:7647380。 EPUB 2022 3月17日。PMID: 35341134“> 35341134 Xu, Xi Zhang, Qian Xiang, Jianfeng Xiong, Dingkun Gui, Youhua Xu
Article Affiliation:Tingting Zhao
Abstract:Objective: To investigate the protective effect and mechanism of astragaloside IV (AS-IV) on damage in human高葡萄糖和高胰岛素刺激的肾小球内皮细胞(GENC)。
结果: 结果: 结果表明,结果表明,AS-IV对Genc的细胞壁架有显着的保护作用。高葡萄糖或胰岛素以浓度依赖性方式抑制细胞活力。高葡萄糖或胰岛素可显着抑制葡萄糖摄取,并促进Genc中活性氧的释放。 AS-IV的给药可显着保留细胞的生存能力;此外,细胞内紧密连接蛋白的表达被上调flammatory cytokines including IL-1and TNFwere decreased, and the AKT-GSK3 pathway participated in modulation of AS-IV in GEnCs cells.
Conclusion: We found in the present study that AS-IV can preserve filtration barrier integrity in glomerular endothelial cells under diabetic设置,其对增加细胞能量代谢和细胞活力的影响,抑制炎症和氧化应激损伤,并增强细胞之间的紧密连接在其中发挥作用;细胞内信号通路AKT-GSK调制了上述函数。我们目前的发现为开发DN提供了新的了解,并提供了一种改善DN的替代方法。